source
- BMS lung drug meets low-dose endpoint in Phase 3 but high dose fails to improve lung functionBristol Myers Squibb reported that its LPA1 antagonist admilparant achieved the primary endpoint in a Phase 3 idiopathic pulmonary fibrosis study at the 60‑mg dose, showing a statistically signific…
- Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drugBristol Myers Squibb announced Monday that two of its late-stage trials have met primary endpoints. The first trial involved its fibrosis program, where the experimental therapy demonstrated the e…